There is considerable research interest in manufacturing blood products for patients using a variety of different cellular sources, including stem cells (embryonic, cord and adult), induced pluripotent stem cells and erythroid cell lines. Red blood cells (RBC) represent a particularly attractive regenerative medicine blood product due to the absence of the nucleus in the final cellular product meaning that they pose a minimal risk in terms of potential for transformation in the recipient, and allogeneic red cell transplants have been given for many years. The number of RBC required in a standard adult therapeutic dose (2 9 10 12 ) is intimidating, but encouraging progress has been made in RBC production under good manufacturing practice from adult stem cells. Already, a cultured RBC (cRBC) mini-transfusion has been conducted in a single volunteer illustrating that the cultured cells can survive in circulation and exhibit no adverse reaction. We must now demonstrate that cRBC are equivalent to the RBC produced naturally in donors by testing laboratory grown blood in multiple volunteers, with the possibility of showing that these cRBC have prolonged survival due to being freshly made reticulocytes. Work is also required on increasing the yield and scaling up cRBC manufacturing to generate clinical quantities of cRBC in a more efficient and cost-effective ways.
Introduction
The manufacture of cultured red blood cells (cRBC) is a goal for blood services and research laboratories around the world in order to secure blood supply and for the provision of the rarer blood types for difficult to transfuse patient groups, such as sickle cell patients who can develop an alloimmune reaction due to multiple transfusions. A culture system that allows the in-depth study of human erythropoiesis in health and disease is also important as a powerful research tool. The manufacture of the numbers of cRBC required for an adult therapeutic dose (approximately 2 9 10 12 cells contained in a conventional erythrocyte transfusion) represents a significant scientific and bioengineering challenge. Successful protocols have been developed to produce 'red cells' using either CD34 + haematopoietic stem cells (HSCs) or peripheral blood mononuclear cells (PBMNCs) derived from adult peripheral blood [1] [2] [3] [4] [5] [6] , umbilical cord blood [6] [7] [8] [9] [10] and embryonic stem cells [11, 12] , although actual yields of reticulocytes and enucleation efficiency vary dramatically depending on starting material (see examples in Table 1 ). Table 1 summarizes some of the key attempts and milestones in the field of human ex vivo erythroid culture. Although outside of the scope of this review, it is important to acknowledge here the considerable work in other species and also cell line work which preceded the human studies and that are still ongoing.
2D liquid culture methodology
Recapitulation of erythropoiesis ex vivo requires combinations of recombinant cytokines and growth factors in order to first expand haematopoietic stem and progenitor Table 1 ). The general consensus is for the inclusion of a primary stage to favour HSC expansion with stem cell factor (SCF), interleukin-3 (IL-3) and erythropoietin (EPO), a secondary erythroblast expansion stage which includes SCF, EPO and transferrin, followed by a terminal differentiation stage with EPO and holotransferrin. Some researchers also modify the culture media by including thrombopoietin (TPO), interleukin-6 (IL-6) and fms-like tyrosine kinase 3 (Flt-3) in the first stage and may also incorporate glucocorticoids [7] to increase expansion prior to differentiation. Several agonists are reported that stimulate self-renewal of early erythroid progenitors including prolyl hydroxylase inhibitors [13] and peroxisome proliferator-activated receptor alpha (PPAR-ɑ) [14] (both alongside glucocorticoid stimulation) and transforming growth factor beta (TGF-b) agonists [15] but as yet these have not been utilized to grow large-scale cultures. Several culture protocols reported to date have successfully generated large numbers of reticulocytes [2, 4, 5, 16] . These culture systems have also been utilized to improve our understanding of erythropoiesis and the assembly of the specialized RBC membrane in health and disease. Two studies of particular note have succeeded in manufacturing enough reticulocytes to be considered truly a transfusable dose, albeit still a minitransfusion or possibly enough for a paediatric dose. The first study by Giarratana et al. used static culture methods to produce 2Á5 ml cRBC from adult CD34
+ starting material obtained by leukapheresis from a volunteer treated with granulocyte colony-stimulating factor (G-CSF) [4] . This study also incorporated hydrocortisone to presumably induce stress erythropoiesis and maximize expansion. The second study by Griffiths et al. used spinner flasks to generate 5 ml cRBC from normal donor cells harvested from a single donor apheresis cone [5] but did not include glucocorticoids. In both cases, the final product produced was, unsurprisingly (as the cells are not circulated during culture), reticulocytes not erythrocytes. The cells had a larger mean cell volume (e.g. Griffiths et al. it was 131 fL (normal range for erythrocytes is 80-199 fL)), slightly lower deformability, possess residual cellular organelles and have detectable levels of membrane proteins not normally found in circulating erythrocytes (CD36/CD71/CD98). The proteome of cRBC is similar to RBC but have higher levels of some proteins, consistent with being reticulocytes [17] . In the body, reticulocytes normally leave the bone marrow and then mature over approximately 48 hrs in the circulation. When injected into a non-obese diabetic SCID (NOD/SCID) mouse model, the reticulocytes produced using both methods lose reticulocytes characteristics and mature to RBC [4, 10] . Importantly, no unexpected differences in antigen expression were observed from the original donor phenotype [5] .
More recently, the Griffiths et al. methodology has been optimized further, producing approximately 10 ml of adult or cord CD34 + -derived cRBC [4, 10] .
Cord blood represents a more abundant source of haematopoietic progenitors than adult blood [18] , and the existence of national cord stem cell banks allows access to a starting material that represents a potentially greater diversity of ethnicities than available via the blood donor pool. Timmins et al. extrapolated from the expansion observed in 1L wave bio-reactors to propose a theoretical large-scale manufacture system for cord blood that could produce 500 units from a single cord blood donation [19] , but as yet no culture of this scale has been reported. The reticulocytes obtained from cord blood have fetal haemoglobin (HbF) rather than adult globin (HbA). The presence of fetal haemoglobin is not anticipated to be a problem as hereditary persistence of high levels of fetal haemoglobin, where fetal globin production continues into adulthood, is a benign condition. Proteomics studies that compared cord blood to adult stem cell produced reticulocytes, where the cultured cord blood reticulocytes were reassuringly similar, differing only in their globin expression and in proteins involved in gas exchange (aquaporin 1 and carbonic anhydrase 1 and 2) [17] . This suggests that with respect to the proteome, there is no barrier for their use in transfusion, other than differences in efficiencies of oxygen uptake and release.
Human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSC) also represent an attractive starting material for blood cell production due to the high proliferative potential of these cells. The caveat with using embryonic cells as a cellular source is that these cells are accompanied with ethical issues and also in vivo generate mostly nucleated erythrocytes while also expressing embryonic globin genes [20] . IPSC are derived from reprogramming adult somatic cells and so have no accompanying ethical issues when generated from consenting donors, but like cord blood-derived cells, these express fetal globins. To date, however, only modest degrees of enucleation and adult haemoglobin expression have been reported for iPSC. A comparison of the proteomes of iPSC erythroblasts differentiated from several sources with erythroblasts generated from adult or cord blood has shown these are highly similar with the expected hallmark contingent of erythroid specific membrane proteins. However, there were some differences in cytoskeletal proteins abundance, which may explain the substantially lower enucleation rates achieved with iPSC [21] .
Animal and human trials of cultured reticulocytes conducted to date
The initial tests of cultured reticulocytes were conducted using NOD/SCID mice model [4] . The stem cell-derived reticulocytes from cord blood have also been evaluated for oxygen delivery to tissues using a SCID exercise model and shown to behave similarly to donor-derived RBC [22] . The challenge however is assessing survival of the reticulocytes in circulation as the cells are recognized as foreign in these mouse models and so are rapidly cleared by resident macrophages, necessitating the use of techniques such as liposome-encapsulated clodronate to specifically deplete macrophages. The most recent tests of adult and cord stem cell produced reticulocytes compared to donor-derived RBC found that higher levels of cultured reticulocytes were present after 24 h compared to a standard donor RBC sample (82% cord and 78% adult cRBC remained while standard donor cells declined rapidly to only 49%), reflecting the fact that these cells are freshly produced [10] . Humanized mouse models are available that facilitate the engraftment of multilineage human haematopoietic cells after human HSC transplantation (see review [23] ), which may prove advantageous for testing cultured RBC products in the future.
In the case of the first proof of principle autologous mini-transfusion by the Giarratana et al., the cultured adult human reticulocytes were Cr 51 -labelled and these were given back to the same volunteer who provided the original mobilized stem cells. The majority of the reticulocytes survived in the circulation after 26 days [4] . These data provide evidence of the feasibility of deriving functional human red cells for clinical use by laboratory culture but a larger trial involving more volunteers is needed, followed by a dose escalation study. In the United Kingdom, using funding provided by the National Institute of Health to form a Blood and Transplant Research Unit in Red Cell products at the University of Bristol and by the UK blood service (NHS Blood and Transplant), we are working towards a clinical trial of reticulocytes produced from adult and cord stem cells in healthy volunteers. This trial is called RESTORE (REcovery and survival of Stem cell Originated REd cells) and is currently in the preparation stages. It will be an allogeneic test of a minitransfusion of reticulocytes produced from adult stem cells compared to the same donor's natural RBC produced in vivo. It is designed to be allogeneic to also inform a second trial which will test reticulocytes produced from cord blood stem cells which by its nature cannot be autologous. The culture method used to produce reticulocytes for the trial will be based on previously described methods by Griffiths et al. which has been further optimized for producing cells under good manufacturing practice (GMP) [5, 10] .
Increasing the yield of reticulocytes to represent more closely an adult therapeutic dose
Despite the successes in recent years for the field of in vitro culture of erythrocytes, the process remains labour intensive and costly. The challenge going forward for cRBC production is that the current culture conditions cause HSCs to be rapidly pushed into erythroid lineage commitment, eventually exhausting the initial stem cell pool and limiting expansion capacity. Furthermore, highdensity culture is difficult due to the increased likelihood of spontaneous terminal differentiation and so large media volumes are currently required (reviewed extensively in [24, 25] ). Future work to increase expansion potential thus maximizing yield will be key, alongside reduction in exogenous cytokine inclusion and medium volumes in an attempt to decrease costs and human intervention. Work also needs to be undertaken to determine an actual therapeutic adult dose of reticulocytes as it is possible that we have set the goal of our cell numbers unnecessarily high by seeking to match the cell numbers provided by traditional adult blood donations, as cRBC represent cells of equivalent age rather than a mixture of ages.
In the bone marrow transplantation field, a variety of strategies have been successfully employed to expand HSC numbers in vitro to enhance bone marrow repopulation. To date, HSC expansion has been achieved using the aryl hydrocarbon agonist SR-1 [26] , delta notch ligand [27] , angiopoietin-like 5 and IGFBP2 [28] , but UM171 [29] , has been demonstrated to be one of the most potent HSC expansion molecules. These may have some utility in increasing the yield of reticulocytes; however, there is also the possibility that these expansion strategies select and amplify stem cells sufficiently for reinstating haematopoiesis in vivo but not for in vitro blood production.
Another option to achieve this is better recapitulation of the bone marrow structure and microenvironment in an attempt to increase yields and the longevity of erythroid cultures. The bone marrow produces RBC for an entire life time, recapitulating even a proportion of the self-renewal potential present in the human bone marrow would greatly increase the potential culture yields ex vivo. For example, this could be achieved by incorporating signals provided by stromal cells such as macrophages [30] [31] [32] and MSC [33] or by utilizing functionalized surfaces or scaffolds [34, 35] .
An alternative strategy is the use of immortalized erythroid progenitor cell lines obtained by cellular transformation. Such lines are theoretically capable of providing an unlimited supply of reticulocytes and require less complicated culture conditions to produce the final product. By immortalizing a late stage cell type, for example, an erythroblast, negates the lengthy differentiation process required for generation of stem cell or iPSC-derived reticulocytes. Erythroid lines have to date been generated using erythroid cells differentiated from human-induced pluripotent stem cells (HiDEP [36] ), cord blood progenitors (HUDEP [36] ; iE2 [37] ) and embryonic stem cells [38] . These lines all express fetal or embryonic globin and have terminal differentiation defects. HiDEP and HUDEP were made by inducible expression of the human papilloma virus 16 proteins HPV16-E6/E7 [36] and have become a useful research tool. The same immortalization technique has recently been successfully used on adult bone marrow CD34 + cells to produce the Bristol Erythroid Line Adult (BEL-A) which are the first human immortalized lines that enucleate (up to 30%) generating reticulocytes [39] . These adult reticulocytes have a proteome similar to in vitro produced reticulocytes and RBC. The challenge now is to increase the enucleation efficiency and also improve the culture conditions so that these cells can be grown at scale.
Cells from donors with attractive RBC phenotypes
There are examples of patients where there is evidence of increased blood production or polycythaemia. Where these patients produce a normal blood phenotype that is utilized for transfusion, it is worth considering these cells as candidates for increasing the yield of manufactured cells unless there is a myeloproliferative risk excluding use for transfusion. Furthermore, large cohorts of normal donors and patients have been sequenced to identify genetic traits, which influence specific blood parameters [40, 41] . These traits could subsequently be explored for use in RBC production under the assumption of a normal phenotype and survival in the circulation. With the availability of iPSC and erythroid line technology comes the possibility of either immortalizing donor cells and/or using gene editing to combine attractive RBC traits, to generate lines from rare blood group phenotypes to service a larger proportion of the patient's population or that can potentially produce higher numbers of reticulocytes, or both.
Conclusion
We are entering an exciting phase of RBC manufacturing where we will soon observe the efficacy of these cells in volunteers given mini-transfusions, which will be the first step towards approval as a cellular therapy for the clinic. The first therapeutic use of a cRBC product will likely be for patients with rare blood group phenotypes where suitable conventional red cell products are difficult to source. Investment will be necessary to scale up the process to an industrial level, coupled with collaborations across research groups employing a wide range of cell biology and bioengineering skills will be required to achieve a considerable increase in yields. Furthermore, the formation of commercial partnerships for the procurement of media and reagents alongside expensive reagents/equivalents produced in house would aid in cost reduction. Whether the final product that reaches the clinic is derived by increasing yield from the donor's natural stem cells, or by producing iPSC or erythroid lines, or cells that have been further genetically manipulated will be defined by efficiencies of the scale up and costs for the individual technologies concerned and also the characteristics of the derived final cellular products. Initially, it is easier to envisage firstgeneration blood products cultured ex vivo being generated from adult stem cells or cord blood. However, iPSC and immortalized lines produced under GMP conditions may follow as second-or third-generation products once technical hurdles are overcome and their safety and efficacy are proven.
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